SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

SVB Leerink Upgrades CymaBay Therapeutics to Outperform, Raises Price Target to $6

SVB Leerink upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Market Perform to Outperform and raises the price target from $2.5 to $6.

Benzinga · 05/12/2020 10:48

SVB Leerink upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Market Perform to Outperform and raises the price target from $2.5 to $6.